69628-97-3

Basic information

• Product Name: toluene-4-sulfonic acid 2-(3-nitrophenyl)ethyl ester
• Synonyms: toluene-4-sulfonic acid 2-(3-nitrophenyl)ethyl ester
• CAS NO: 69628-97-3
• Molecular Weight: 321.354
• Mol File: 69628-97-3.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: toluene-4-sulfonic acid 2-(3-nitrophenyl)ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: toluene-4-sulfonic acid 2-(3-nitrophenyl)ethyl ester(69628-97-3)
• EPA Substance Registry System: toluene-4-sulfonic acid 2-(3-nitrophenyl)ethyl ester(69628-97-3)

Safety Data

• Hazardous Substances Data: 69628-97-3(Hazardous Substances Data)

Upstream product

• 52022-77-2 2-(3-nitrophenyl)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 1877-73-2 3-nitro-benzeneacetic acid 

Downstream Products

• 402508-77-4 thioacetic acid S-[2-(3-nitrophenyl)ethyl] ester 
• 1214924-42-1 (1S,2S,3R,4R,5R)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)-5-(3-nitrophenethylamino)bicyclo[2.2.1]heptane-2-carboxamide 
• 1214923-96-2 (1R,2S,3R,4R)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)-5-((3-nitrophenethyl-amino)methyl)bicyclo[2.2.1]heptane-2-carboxamide 
• 1214923-85-9 (1S,2S,3S,4S,5R)-3-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-5-{[2-(3-nitrophenyl)ethyl]thio}bicyclo[2.2.1]heptane 
• 1214923-86-0 (1S,2S,3S,4S,5R)-5-{[2-(3-aminophenyl)ethyl]thio}-3-[(2-chloro-5-fluoropyrimidin-4-yl)amino]bicyclo[2.2.1]heptane-2-carboxamide 
• 1257078-41-3 2-(methyl(3-nitrophenethyl)amino)ethanol 
• 1050530-06-7 C₂₆H₂₂N₂O₆ 
• 97351-96-7 3-nitro-N,N-dipropylbenzeneethanamine 
• 80641-92-5 N-(2-(m-nitrophenyl)ethyl)-1,4-diazabicyclo<2.2.2>octanium tosylate 
• 103544-23-6 3'-<2-(N,N-di-n-propylamino)ethyl>aniline 

Relevant articles and documents

Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction

Disruption of EZH2-embryonic ectoderm development (EED) protein-protein interaction (PPI) is a new promising cancer therapeutic strategy. We have previously reported the discovery of astemizole, a small-molecule inhibitor targeting the EZH2-EED PPI. Herein, we report the cocrystal structure of EED in complex with astemizole at 2.15 ?. The structure elucidates the detailed binding mode of astemizole to EED and provides a structure-guided design for the discovery of a novel EZH2-EED interaction inhibitor, DC-PRC2in-01, with an affinityKdof 4.56 μM. DC-PRC2in-01 destabilizes the PRC2 complex, thereby leading to the degradation of PRC2 core proteins and the decrease of global H3K27me3 levels in cancer cells. The proliferation of PRC2-driven lymphomas cells is effectively inhibited, and the cell cycle is arrested in the G0/G1 phase. Together, these data demonstrate that DC-PRC2in-01 could be an effective chemical probe for investigating the PRC2-related physiology and pathology and providing a promising chemical scaffold for further development.

PYRIMIDINE INHIBITORS OF KINASE ACTIVITY

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.

Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a -agonist δ-antagonist and δ-inverse agonists

Enantiomeric N-phenethyl-m-hydroxyphenylmorphans with various substituents in the ortho, meta or para positions of the aromatic ring in the phenethylamine side-chain (chloro, hydroxy, methoxy, nitro, methyl), as well as a pyridylethyl and a indolylethyl m